• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pharmacogenetic Influences Over Mavacamten Pharmacokinetics: Considerations for the Treatment of Individuals With Hypertrophic Cardiomyopathy.

作者信息

McGurk Kathryn A, Bilgehan Nagme, Ware James S

机构信息

National Heart and Lung Institute and MRC Laboratory of Medical Sciences, Imperial College London, UK (K.A.M., N.B., J.S.W.).

Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, MA (K.A.M., J.S.W.).

出版信息

Circulation. 2024 Jun 4;149(23):1786-1788. doi: 10.1161/CIRCULATIONAHA.123.066916. Epub 2024 Jun 3.

DOI:10.1161/CIRCULATIONAHA.123.066916
PMID:38829931
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7616064/
Abstract
摘要

相似文献

1
Pharmacogenetic Influences Over Mavacamten Pharmacokinetics: Considerations for the Treatment of Individuals With Hypertrophic Cardiomyopathy.药代遗传学对马伐卡坦药代动力学的影响：肥厚型心肌病患者治疗的考量
Circulation. 2024 Jun 4;149(23):1786-1788. doi: 10.1161/CIRCULATIONAHA.123.066916. Epub 2024 Jun 3.
2
Mavacamten decreases maximal force and Ca sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy.在肥厚型心肌病的N47K-肌球蛋白调节轻链小鼠模型中，马伐卡坦降低最大力量和钙敏感性。
Am J Physiol Heart Circ Physiol. 2021 Feb 1;320(2):H881-H890. doi: 10.1152/ajpheart.00345.2020. Epub 2020 Dec 18.
3
Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.马卡丹特对梗阻性肥厚型心肌病有症状患者超声心动图特征的影响。
J Am Coll Cardiol. 2021 Dec 21;78(25):2518-2532. doi: 10.1016/j.jacc.2021.09.1381.
4
Genotype Influences Mavacamten Responsiveness in Obstructive Hypertrophic Cardiomyopathy.基因型影响梗阻性肥厚型心肌病对马伐卡坦的反应性。
Mayo Clin Proc. 2024 Feb;99(2):341-343. doi: 10.1016/j.mayocp.2023.11.019.
5
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.马卡丹特治疗有症状梗阻性肥厚型心肌病（EXPLORER-HCM）的随机、双盲、安慰剂对照、3 期临床试验
Lancet. 2020 Sep 12;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X. Epub 2020 Aug 29.
6
Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension: Post-Hoc Analysis of the EXPLORER-HCM Trial.马卡丹特治疗伴或不伴高血压的梗阻性肥厚型心肌病：EXPLORER-HCM 试验的事后分析。
JACC Heart Fail. 2024 Mar;12(3):567-579. doi: 10.1016/j.jchf.2023.07.030. Epub 2023 Oct 18.
7
Exploring New and Old Therapies for Obstructive Hypertrophic Cardiomyopathy: Mavacamten in Perspective.探索梗阻性肥厚型心肌病的新旧疗法：马伐卡坦的前景
Circulation. 2021 Mar 23;143(12):1181-1183. doi: 10.1161/CIRCULATIONAHA.120.051330. Epub 2021 Mar 22.
8
Considerations for managed care pharmacy in evaluating mavacamten, a novel agent for obstructive hypertrophic cardiomyopathy.评估新型梗阻性肥厚型心肌病药物 mavacamten 时需考虑的管理式医疗药学因素。
J Manag Care Spec Pharm. 2022 Mar;28(3):376-378. doi: 10.18553/jmcp.2022.28.3.376.
9
Mavacamten (CAMZYOS) First-in-Class Small-Molecule Myosin Inhibitor for Treatment of Obstructive Hypertrophic Cardiomyopathy.马伐卡坦（CAMZYOS）：用于治疗梗阻性肥厚型心肌病的一流小分子肌球蛋白抑制剂。
Clin Nurse Spec. 2024;38(3):E3. doi: 10.1097/NUR.0000000000000822.
10
Mavacamten (CAMZYOS) First-in-Class Small-Molecule Myosin Inhibitor for Treatment of Obstructive Hypertrophic Cardiomyopathy.马伐卡坦（CAMZYOS）：用于治疗梗阻性肥厚型心肌病的首款小分子肌球蛋白抑制剂。
Clin Nurse Spec. 2024;38(3):119-121. doi: 10.1097/NUR.0000000000000821.

引用本文的文献

1
Efficacy of Mavacamten in Reducing Cardiac Obstruction in an Elderly Patient with Hypertrophic Cardiomyopathy: A Case Study.马伐卡坦对一名老年肥厚型心肌病患者减轻心脏梗阻的疗效：一项病例研究
Am J Case Rep. 2025 Apr 18;26:e946956. doi: 10.12659/AJCR.946956.
2
French-Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of Mavacamten.法语区药物基因组学网络（RNPGx）关于mavacamten临床应用的建议。
Clin Pharmacol Ther. 2025 Feb;117(2):387-397. doi: 10.1002/cpt.3502. Epub 2024 Nov 25.

本文引用的文献

1
Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial.马卡丹特治疗中国有症状梗阻性肥厚型心肌病患者的疗效：EXPLORER-CN 随机临床试验。
JAMA Cardiol. 2023 Oct 1;8(10):957-965. doi: 10.1001/jamacardio.2023.3030.
2
Exploring New and Old Therapies for Obstructive Hypertrophic Cardiomyopathy: Mavacamten in Perspective.探索梗阻性肥厚型心肌病的新旧疗法：马伐卡坦的前景
Circulation. 2021 Mar 23;143(12):1181-1183. doi: 10.1161/CIRCULATIONAHA.120.051330. Epub 2021 Mar 22.
3
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.马卡丹特治疗有症状梗阻性肥厚型心肌病（EXPLORER-HCM）的随机、双盲、安慰剂对照、3 期临床试验
Lancet. 2020 Sep 12;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X. Epub 2020 Aug 29.
4
Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial.Mavacamten 治疗梗阻性肥厚型心肌病的临床试验。
Ann Intern Med. 2019 Jun 4;170(11):741-748. doi: 10.7326/M18-3016. Epub 2019 Apr 30.
5
In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin.马伐卡坦（一种新型小分子β心肌肌球蛋白变构调节剂）的体外和体内药代动力学特征
Xenobiotica. 2019 Jun;49(6):718-733. doi: 10.1080/00498254.2018.1495856. Epub 2018 Oct 1.